AUTHOR=Hsueh Pei-Chun , Chang Kai-Ping , Liu Hao-Ping , Chiang Wei-Fan , Chan Xiu-Ya , Hung Chu-Mi , Chu Lichieh Julie , Wu Chih-Ching 

TITLE=Development of a salivary autoantibody biomarker panel for diagnosis of oral cavity squamous cell carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.968570

DOI=10.3389/fonc.2022.968570

ISSN=2234-943X

ABSTRACT=<p>Oral cavity squamous cell carcinoma (OSCC) is a destructive disease with increasing incidence. OSCC is usually diagnosed at an advanced stage, which leads to poor outcomes of OSCC patients. Currently, there is a lack of biomarkers with sufficient effectiveness in early diagnosis of OSCC. To ameliorate OSCC screening, we evaluated the performances of salivary autoantibodies (auto-Abs) to nine proteins (ANXA2, CA2, ISG15, KNG1, MMP1, MMP3, PRDX2, SPARC, and HSPA5) as OSCC biomarkers. A multiplexed immunoassay using a fluorescence bead-based suspension array system was established for simultaneous assessment of the salivary levels of the above nine auto-Abs and a known OSCC-associated auto-Ab, anti-p53. Compared to healthy individuals (<italic>n</italic> = 140), the salivary levels of nine auto-Abs were significantly elevated in OSCC patients (<italic>n</italic> = 160). Notably, the salivary levels of the 10 auto-Abs in the early-stage OSCC patients (<italic>n</italic> = 102) were higher than that in the healthy group. Most importantly, utilizing a marker panel consisting of anti-MMP3, anti-PRDX2, anti-SPARC, and anti-HSPA5 for detection of early-stage OSCC achieved a sensitivity of 63.8% with a specificity of 90%. Collectively, herein we established a multiplex auto-Ab platform for OSCC screening, and demonstrated a four-auto-Ab panel which shows clinical applicability for early diagnosis of OSCC.</p>